Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28.161
Filter
1.
J Ethnopharmacol ; 336: 118701, 2025 Jan 10.
Article in English | MEDLINE | ID: mdl-39153519

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Mouthwashes based on medicinal plants have demonstrated benefits in controlling plaque and inflammation, acting positively on the oral hygiene of patients with gingivitis. In traditional medicine, Punica granatum L. has been used to treat oral diseases in countries in Europe, Asia, North America, and Africa. AIM OF THE STUDY: The present study aimed to conduct a comprehensive review on the dental applications of Punica granatum L. for the treatment of gingivitis, including ethnomedicinal uses, analysis of randomized clinical trials, antibacterial activity against Porphyromonas gingivalis, mechanisms of action of phytochemicals isolated from this plant, and preclinical toxicity. MATERIALS AND METHODS: The literature was retrieved from Google Scholar, PubMed®, SciELO, and ScienceDirect®, since the first report published on the topic in 2001 until March 2024. RESULTS: Several clinical trials have demonstrated that mouthwashes containing P. granatum have equal or better efficacy than chlorhexidine in treating patients with gingivitis, confirming the indications for use of this plant by traditional communities. However, reports on the in vitro antibacterial activity of extracts from the fruits of this plant have not shown clinical relevance against the pathogen P. gingivalis. The ellagitannin punicalagin isolated from P. granatum has shown potential against several strains of Gram-positive and Gram-negative bacteria, but, to date, this compound has not yet been tested against P. gingivalis. It is likely that the mechanisms of action of flavonoids, such as quercetin, are involved in the inhibition of the activities of the RgpA, RgpB, and Kgp proteases of P. gingivalis. CONCLUSIONS: In summary, natural products obtained from P. granatum do not present toxic side effects and can be considered as possible substitutes of commercial products recommended for the treatment of gingivitis and other oral diseases.


Subject(s)
Anti-Bacterial Agents , Gingivitis , Plant Extracts , Porphyromonas gingivalis , Randomized Controlled Trials as Topic , Humans , Gingivitis/drug therapy , Porphyromonas gingivalis/drug effects , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Pomegranate/chemistry , Medicine, Traditional , Animals , Phytotherapy
2.
J Ethnopharmacol ; 336: 118730, 2025 Jan 10.
Article in English | MEDLINE | ID: mdl-39181280

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Acute lung injury (ALI) can lead to respiratory failure and even death. KAT2A is a key target to suppress the development of inflammation. A herb, perilla frutescens, is an effective treatment for pulmonary inflammatory diseases with anti-inflammatory effects; however, its mechanism of action remains unclear. AIM OF THE STUDY: The purpose of this study was to investigate the therapeutic effect and underlying mechanism of perilla frutescens leaf extracts (PLE), in the treatment of ALI by focusing on its ability to treat inflammation. MATERIALS AND METHODS: In vivo and in vitro models of ALI induced by LPS. Respiratory function, histopathological changes of lung, and BEAS-2B cells damage were assessed upon PLE. This effect is also tested under conditions of KAT2A over expression and KAT2A silencing. RESULTS: PLE significantly attenuated LPS-induced histopathological changes in the lungs, improved respiratory function, and increased survival rate from LPS stimuation background in mice. PLE remarkably suppressed the phosphorylation of STAT3, AKT, ERK (1/2) and the release of cytokines (IL-6, TNF-α, and IL-1ß) induced by LPS via inhibiting the expression of KAT2A. CONCLUSIONS: PLE has a dose-dependent anti-inflammatory effect by inhibiting KAT2A expression to suppress LPS-induced ALI n mice. Our study expands the clinical indications of the traditional medicine PLE and provide a theoretical basis for clinical use of acute lung injury.


Subject(s)
Acute Lung Injury , Lipopolysaccharides , Perilla frutescens , Plant Extracts , Plant Leaves , Animals , Acute Lung Injury/drug therapy , Acute Lung Injury/pathology , Acute Lung Injury/chemically induced , Perilla frutescens/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Plant Leaves/chemistry , Male , Mice , Humans , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/isolation & purification , Anti-Inflammatory Agents/therapeutic use , Cytokines/metabolism , Cell Line , Mice, Inbred C57BL , Lung/drug effects , Lung/pathology , Lung/metabolism , Disease Models, Animal
3.
J Ethnopharmacol ; 336: 118726, 2025 Jan 10.
Article in English | MEDLINE | ID: mdl-39181279

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Sea buckthorn (Hippophae rhamnoides), a traditional Tibetan medicinal herb, exhibits protective effects against cardiovascular and respiratory diseases. Although Sea buckthorn extract (SBE) has been confirmed to alleviate airway inflammation in mice, its therapeutic effect and underlying mechanism on chronic obstructive pulmonary disease (COPD) requires further clarification. AIM OF THE STUDY: To elucidate the alleviative effect and molecular mechanism of SBE on lipopolysaccharides (LPS)/porcine pancreatic elastase (PPE)-induced COPD by blocking ferroptosis. METHODS: The anti-ferroptotic effects of SBE were evaluated in human BEAS-2B bronchial epithelial cells using CCK8, RT-qPCR, western blotting, and transmission electron microscopy. Transwell was employed to detect chemotaxis of neutrophils. COPD model was induced by intranasally administration of LPS/PPE in mice and measured by alterations of histopathology, inflammation, and ferroptosis. RNA-sequencing, western blotting, antioxidant examination, flow cytometry, DARTS, CETSA, and molecular docking were then used to investigate its anti-ferroptotic mechanisms. RESULTS: In vitro, SBE not only suppressed erastin- or RSL3-induced ferroptosis by suppressing lipid peroxides (LPOs) production and glutathione (GSH) depletion, but also suppressed ferroptosis-induced chemotactic migration of neutrophils via reducing mRNA expression of chemokines. In vivo, SBE ameliorated LPS/PPE-induced COPD phenotypes, and inhibited the generation of LPOs, cytokines, and chemokines. RNA-sequencing showed that p53 pathway and mitogen-activated protein kinases (MAPK) pathway were implicated in SBE-mediated anti-ferroptotic action. SBE repressed erastin- or LPS/PPE-induced overactivation of p53 and MAPK pathway, thereby decreasing expression of diamine acetyltransferase 1 (SAT1) and arachidonate 15-lipoxygenase (ALOX15), and increasing expression of glutathione peroxidase 4 (GPX4) and solute carrier family 7 member 11 (SLC7A11). Mechanistically, erastin-induced elevation of reactive oxygen species (ROS) was reduced by SBE through directly scavenging free radicals, thereby contributing to its inhibition of p53 and MAPK pathways. CETSA, DARTS, and molecular docking further showed that ROS-generating enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) may be the target of SBE. Overexpression of NOX4 partially impaired the anti-ferroptotic activity of SBE. CONCLUSION: Our results demonstrated that SBE mitigated COPD by suppressing p53 and MAPK pro-ferroptosis pathways via directly scavenging ROS and blocking NOX4. These findings also supported the clinical application of Sea buckthorn in COPD therapy.


Subject(s)
Ferroptosis , Hippophae , Plant Extracts , Pulmonary Disease, Chronic Obstructive , Reactive Oxygen Species , Tumor Suppressor Protein p53 , Ferroptosis/drug effects , Pulmonary Disease, Chronic Obstructive/drug therapy , Animals , Humans , Reactive Oxygen Species/metabolism , Hippophae/chemistry , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Tumor Suppressor Protein p53/metabolism , Mice , Male , Mice, Inbred C57BL , Cell Line , Lipopolysaccharides/toxicity , MAP Kinase Signaling System/drug effects , Disease Models, Animal , Molecular Docking Simulation
4.
J Ethnopharmacol ; 336: 118731, 2025 Jan 10.
Article in English | MEDLINE | ID: mdl-39182698

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Calyptrochilum emarginatum (Afzel. Ex Sw.) Schltr. (Orchidaceae) is a traditional medicinal plant known for its antimicrobial properties and efficacy in managing convulsive fever and menstrual disorders and addressing conditions such as malaria, tuberculosis, and cough. AIM OF THE STUDY: The study aims to examine the memory-enhancing and neuroprotective properties of ethanol extract of Calyptrochilum emarginatum leaves (EECEL) in scopolamine-induced amnesia mice model. MATERIALS AND METHODS: Forty-two male mice were divided into six groups (n = 7). Group 1 served as control, administered distilled water (10 mL/kg, p. o), group 2 received scopolamine only (3 mg/kg, i. p.), groups 3 to 6 received pretreatments of EECEL (50, 100, and 200 mg/kg, p. o.) and donepezil (1 mg/kg, p. o.) 30 min before scopolamine (3 mg/kg), for seven days. Following treatments, behavioral (learning and memory) assessments were carried out, while biochemical (acetylcholinesterase activity, oxidative stress markers, inflammatory cytokines markers) and histological evaluations were done after euthanasia. RESULTS: Scopolamine significantly impaired spatial, long term and recognition memory. Nevertheless, administration of EECEL (50, 100, and 200 mg/kg orally) enhanced memory function in mice, as observed in the Y maze [F (5, 30) = 20.23, p < 0.0001], Morris water maze [F (10, 90) = 3.105, p = 0.0019; [F (5, 30) = 21.13, p < 0.0001]], and novel object recognition tasks [F (5, 30) = 37.22, p < 0.0001)]. Scopolamine-treated mice exhibited significant dysfunction in the cholinergic system, as evidenced by elevated AChE activity [0.099 ± 0.005 vs. 0.063 ± 0.004 mol/min/g] with an elevation in oxidative stress. On the other hand, administration of EECEL counteracted these consequences by reducing AChE activity, mitigating oxidative damage, reducing pro-inflammatory cytokines, and preventing degeneration of neurons. CONCLUSION: The results demonstrated that EECEL effectively mitigates scopolamine-induced memory impairment via an oxido-inflammatory mechanism and modulation of the central cholinergic system.


Subject(s)
Amnesia , Ethanol , Neuroprotective Agents , Orchidaceae , Plant Extracts , Plant Leaves , Scopolamine , Animals , Male , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Mice , Amnesia/drug therapy , Amnesia/chemically induced , Ethanol/chemistry , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Neuroprotective Agents/isolation & purification , Orchidaceae/chemistry , Oxidative Stress/drug effects , Acetylcholinesterase/metabolism , Maze Learning/drug effects , Disease Models, Animal , Memory/drug effects , Solvents/chemistry , Donepezil/pharmacology , Donepezil/therapeutic use
5.
ScientificWorldJournal ; 2024: 4420431, 2024.
Article in English | MEDLINE | ID: mdl-39228457

ABSTRACT

Traditional medicinal plants (TMPs) are a significant part of people's quality of life, offering a natural substitute for modern drugs with numerous side effects. In Tanzania, data on antiasthmatic TMPs are highly fragmented. This review, a comprehensive compilation of ethnobotanical research evidence, aimed to provide a thorough understanding of TMPs used by the locals for asthma management and identify species that have already been investigated in preclinical studies. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. To gather relevant literature on antiasthmatic TMPs used by Tanzanians, a web search using electronic databases (Scopus, PubMed, ProQuest, Academic Library, Web of Science, SciFinder, Wiley Online Library, Google Scholar, ScienceDirect, and African Journals Online) was conducted. The scientific names were verified through the Plants of the World Online database, and the collected information was analysed for descriptive statistics using Microsoft Excel software. The ethnomedicinal information was obtained from 24 different articles. Microsoft Excel software was used to analyse the data using descriptive statistics. A total of 62 TMPs belonging to 33 families were identified. Species of the Fabaceae (14.5%) and Rubiaceae families (8.1%) are the most utilized. The analysis revealed that trees (42.0%) and leaves (40.0%) are the most utilized life forms and plant parts, respectively. Most plant materials (59.7%) used to make remedies were collected from the wild environment. Decoction (55.0%) is the dominant preparation method of remedies, and the majority (69.0%) were orally administered. Of the recorded TMPs, 22.6% had their in vivo antiasthmatic activity reported in the literature. The review also highlighted the strategic significance of preparations of remedies made from TMPs for discovering and developing new antiasthmatic drugs. However, the need to identify the molecular targets of action and toxicological aspects of the TMPs should be considered.


Subject(s)
Asthma , Ethnopharmacology , Plants, Medicinal , Plants, Medicinal/chemistry , Tanzania , Humans , Ethnopharmacology/methods , Asthma/drug therapy , Anti-Asthmatic Agents/therapeutic use , Medicine, African Traditional/methods , Phytotherapy/methods , Plant Extracts/therapeutic use
6.
Indian J Pharmacol ; 56(4): 260-267, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-39250623

ABSTRACT

OBJECTIVE: Liver derangement underlies the development of metabolic syndrome in perimenopause. Previously, we have observed that durva swaras (DS) improved metabolic-associated fatty liver disease (MAFLD) and abnormal liver enzymes (aspartate aminotransferase and alanine aminotransferase) along with other complications of menopause in ovariectomized rats. We aimed to decipher the hepatoprotective mechanisms of DS in acetaminophen (APAP)-induced liver injury model, which is analogous to the pathophysiology of MAFLD. MATERIALS AND METHODS: Male Swiss albino mice were distributed into three groups at random. Group I (Control) was administered with vehicle (distilled water) for 7 days. Group II (APAP) received vehicle for the first 6 days and APAP (350 mg/kg - single dose) on the 7th day. Group III (APAP + D) received test compound DS (quality complied) at a dose of 133 mg/kg for 6 days and APAP (350 mg/kg - single dose) on the 7th day. Subsequently, blood and liver tissues were subjected to biochemical, ultrastructural, and gene expression analysis. RESULTS: DS pretreatment protected the liver from APAP-induced disruption of sinusoids and necrosis. DS prevented the elevation of liver enzymes - AST and ALT induced by APAP. Importantly, DS inhibited the APAP-elicited increase in messenger ribonucleic acid levels of hepatic nuclear factor-kappa beta (NF-κB) and pro-inflammatory cytokines, namely interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha. Moreover, DS activated gene expression of nuclear factor erythroid 2-related factor 2 and liver-X-receptor-alpha (LXR-α) to combat the liver damage. CONCLUSION: DS hinders APAP-induced liver damage by activating LXR-α and inhibiting the NF-κB-associated pro-inflammatory cytokine gene expression. These observations confirm the protective role of DS in metabolic dysfunction-associated liver conditions.


Subject(s)
Acetaminophen , Chemical and Drug Induced Liver Injury , Animals , Male , Mice , Chemical and Drug Induced Liver Injury/prevention & control , Chemical and Drug Induced Liver Injury/drug therapy , Acetaminophen/toxicity , Plant Extracts/pharmacology , Plant Extracts/administration & dosage , Plant Extracts/therapeutic use , Disease Models, Animal , Liver/drug effects , Liver/metabolism , Liver/pathology , Biomarkers/blood , Alanine Transaminase/blood , NF-kappa B/metabolism , Cytokines/metabolism , Aspartate Aminotransferases/blood , Inflammation/drug therapy
7.
JMIR Res Protoc ; 13: e57287, 2024 Sep 10.
Article in English | MEDLINE | ID: mdl-39255475

ABSTRACT

BACKGROUND: The thyroid gland is an endocrine gland that has an impact on the body's general metabolism. Thus, the secretions of the thyroid gland can modify the overall metabolism of the entire body. The prevalence of hypothyroidism is increasing quickly, with rates of 2%-5% in affluent countries and 11% in India. Individuals diagnosed with hypothyroidism need to take medication for the rest of their lives, resulting in significant stress. Therefore, conducting a study in this area is imperative. OBJECTIVE: This study aims to assess the effectiveness of the therapeutic enema (Kshar Basti) and oral Kanchanar Guggul in the treatment of hypothyroidism. METHODS: The trial group (n=45) will receive a therapeutic enema (Kshar Basti) followed by oral Ayurvedic drugs for 180 days. The control group (n=45) will be given levothyroxine tablets at a dosage of 1.6 µg/kg/day for the same duration. The objective is to examine the alterations in thyroid stimulating hormone (TSH) levels before and after the treatment. RESULTS: Any deviation of the serum TSH by more than 20% from the initial values, while keeping triiodothyronine (T3), and thyroxine (T4) levels within the normal range, will be deemed statistically significant. Consequently, we anticipate a statistically significant variation in serum TSH levels between the therapeutic enema and Kanchanar Guggul treatments. Presently, the drug preparation operations are in progress. We expect to start enrolling patients in June 2024, do data analysis in December 2025, and acquire results by early 2026, marking the end of this trial. CONCLUSIONS: This study will evaluate the efficacy of the therapeutic enema, specifically Kshar Basti, in treating hypothyroidism. Furthermore, more research can determine the efficacy of a therapeutic enema (Kshar Basti) in treating overt hypothyroidism and hypothyroidism during pregnancy. TRIAL REGISTRATION: Clinical Trials Registry India CTRI/2023/05/052389; https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=Nzk1NjY=&Enc=&userName=052389. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/57287.


Subject(s)
Hypothyroidism , Thyroxine , Humans , Hypothyroidism/drug therapy , Thyroxine/therapeutic use , India , Adult , Female , Male , Medicine, Ayurvedic , Enema , Plant Gums/therapeutic use , Commiphora/chemistry , Randomized Controlled Trials as Topic , Plant Extracts/therapeutic use , Plant Extracts/administration & dosage , Middle Aged
8.
Syst Rev ; 13(1): 238, 2024 Sep 19.
Article in English | MEDLINE | ID: mdl-39300549

ABSTRACT

BACKGROUND: Arecae Semen is a traditional herbal medicine widely used in the medical service and food industry, but in recent years, the carcinogenesis of edible Arecae Semen chewing has aroused comprehensive attention, therefore it is necessary to evaluate its medicinal properties. Increasing evidence has shown that Arecae Semen Compounds (ASC) possess antidepressant ability. This study aimed to evaluate the effectiveness and safety of ASC in the treatment of depression. METHODS: We retrieved articles in eight databases from their inception to May 2024. Randomized controlled trials (RCTs) comparing the effects of ASC alone or combined with routine treatment in patients with depression were identified. The Cochrane risk of bias (ROB) tool (ROB 2) was used for assessing the ROB in the included trials. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the certainty of the evidence for the review outcomes. The outcomes included Hamilton depression rating scale (HAMD) scores, depression-related symptoms, serum dopamine levels, and adverse events. Stata 14.0 was used for data analysis calculating standardized mean difference (SMD) for continuous outcomes and relative risk (RR) for binary outcomes, both with 95% confidence intervals (CI). RESULTS: Nine RCTs involving 787 patients were included in this review. ASC lowered HAMD scores (SMD - 3.43, 95% CI - 5.24 to - 1.61; I2 = 95.2%, P < 0.001), alleviated depression-related symptoms, increased serum dopamine levels, and reduced the incidence of adverse events slightly (RR 0.18, 95% CI 0.04 to 0.77; I2 = 0, P = 0.775) compared with the control group. Publication bias might account for the asymmetrical presentation of funnel plots. Meta-regression analysis revealed that regarding HAMD scores, there was no significant relationship with duration, sample size, or treatment strategy. The evidence of the outcomes was of very low certainty. CONCLUSIONS: ASC may achieve better therapeutic effects, alleviate depression-related symptoms with a lower incidence of adverse events, and provide a potentially effective and safe complementary therapy for patients with depression. However, the evidence is very uncertain so further researches are required to validate our results and explore clinical implications of Arecae Semen in depth. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022361150.


Subject(s)
Depression , Humans , Depression/drug therapy , Antidepressive Agents/therapeutic use , Randomized Controlled Trials as Topic , Phytotherapy , Plant Extracts/therapeutic use , Treatment Outcome
9.
J Pak Med Assoc ; 74(5 (Supple-5)): S36-S38, 2024 May.
Article in English | MEDLINE | ID: mdl-39221796

ABSTRACT

Objectives: To examine the effect of date fruit extract and honey in increasing haemoglobin levels in pregnant women. METHODS: The quasi-experimental study was conducted from July to August 2022 in Rumbai Pesisir Subdistric, Pekanbaru, Indonesia, and comprised anaemic pregnant women with haemoglobin levels <11gm/dl who were not consuming iron tablets or blood boosters. They were given honey and date extracts 2 tablespoons twice daily for two weeks. Haemoglobin level was checked at baseline and then at the end of each week of intervention. Data was analysed using SPSS version 20 and quantitative method by using bivariate analysis. RESULTS: Of the 50 women, 59(98%) were aged 20-35 years, and 1(2%) was aged >35 years. Besides, 21(42%) women were in the second trimester, 17(34%) in third, and 12(24%) in the first trimester of pregnancy. The increase in haemoglobin levels post-intervention was highly significant (p=0.0001). CONCLUSIONS: Date fruit extract and honey increased haemoglobin level of pregnant women.


Subject(s)
Hemoglobins , Honey , Phoeniceae , Plant Extracts , Humans , Female , Pregnancy , Adult , Hemoglobins/analysis , Plant Extracts/therapeutic use , Young Adult , Phoeniceae/chemistry , Bees , Pregnancy Complications, Hematologic/blood , Pregnancy Complications, Hematologic/drug therapy , Indonesia , Animals , Anemia/drug therapy
10.
PLoS One ; 19(9): e0296424, 2024.
Article in English | MEDLINE | ID: mdl-39302939

ABSTRACT

In this study, we investigated the neuroprotective effect of a water extract of ginseng (WEG) obtained via low-temperature extraction of the brain of mice with Parkinson's disease (PD) and the ameliorative effect on the damaged intestinal system for the treatment of dyskinesia in PD mice. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was injected intraperitoneally into male C57BL/6 mice to establish a PD model, and WEG was given via oral gavage. The results indicated that WEG could protect the damaged neuronal cells of the mice brain, inhibit the aggregation of α-synuclein (α-Syn) in the brain, and increase the positive expression rate of tyrosine hydroxylase (TH). WEG significantly improved intestinal damage and regulated intestinal disorders (P<0.05). WEG intervention increased the levels of beneficial bacteria, such as Lactobacillus, and normalized the abundance and diversity of colonies in the intestine of mice. Our results suggested that WEG protected neurons in the brain of PD mice via inhibiting the aggregation of α-Syn in the brain and increasing the positive expression level of TH in the brain. WEG regulated the gut microbiota of mice, improved the behavioral disorders of PD mice, and offered some therapeutic effects on PD mice.


Subject(s)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine , Mice, Inbred C57BL , Panax , Plant Extracts , alpha-Synuclein , Animals , Male , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Panax/chemistry , Mice , alpha-Synuclein/metabolism , 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/adverse effects , Brain/drug effects , Brain/metabolism , Brain/pathology , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Disease Models, Animal , Water/chemistry , Parkinsonian Disorders/drug therapy , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/chemically induced , Tyrosine 3-Monooxygenase/metabolism , Gastrointestinal Microbiome/drug effects
11.
PLoS One ; 19(9): e0290185, 2024.
Article in English | MEDLINE | ID: mdl-39302982

ABSTRACT

INTRODUCTION: Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents. METHODS AND ANALYSIS: Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label, dose escalation study across three Canadian sites. Study participants will receive escalating doses of a CBD-enriched CHE (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day. The primary objective of this study is to determine the safety and tolerability of CBD-enriched CHE in adolescents with chronic migraine. Secondary objectives of this study will inform the development of subsequent randomized controlled trials and include investigating the relationship between the dose escalation and change in the frequency of headache, impact and intensity of pain, changes in sleep, mood, function, and quality of life. Exploratory outcomes include investigating steady-state trough plasma levels of bioactive cannabinoids and investigating how pharmacogenetic profiles affect cannabinoid metabolism among adolescents receiving CBD-enriched CHE. DISCUSSION: This protocol was co-designed with youth and describes a tolerability clinical trial of CBD-enriched CHE in adolescents with chronic headaches that have not responded to conventional therapies. This study is the first clinical trial on cannabis products in adolescents with chronic headaches and will inform the development of future comparative effectiveness clinical trials. TRIAL REGISTRATION: CAN-CHA trial is registered with ClinicalTrials.gov with a number of register NCT05337033.


Subject(s)
Cannabidiol , Plant Extracts , Humans , Adolescent , Cannabidiol/adverse effects , Cannabidiol/administration & dosage , Cannabidiol/therapeutic use , Plant Extracts/therapeutic use , Plant Extracts/adverse effects , Plant Extracts/administration & dosage , Male , Female , Cannabis/chemistry , Canada , Headache Disorders/drug therapy , Migraine Disorders/drug therapy
12.
CNS Neurosci Ther ; 30(9): e14914, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39238068

ABSTRACT

AIMS: Alzheimer's disease (AD) is a neurodegenerative disorder with limited treatment options. This study aimed to investigate the therapeutic effects of Ginkgo biloba leaf extract (GBE) on AD and explore its potential mechanisms of action. METHODS: Key chemical components of GBE, including quercetin, luteolin, and kaempferol, were identified using network pharmacology methods. Bioinformatics analysis revealed their potential roles in AD through modulation of the PI3K/AKT/NF-κB signaling pathway. RESULTS: Mouse experiments demonstrated that GBE improved cognitive function, enhanced neuronal morphology, and reduced serum inflammatory factors. Additionally, GBE modulated the expression of relevant proteins and mRNA. CONCLUSION: GBE shows promise as a potential treatment for AD. Its beneficial effects on cognitive function, neuronal morphology, and inflammation may be attributed to its modulation of the PI3K/AKT/NF-κB signaling pathway. These findings provide experimental evidence for the application of Ginkgo biloba leaf in AD treatment and highlight its potential mechanisms of action.


Subject(s)
Alzheimer Disease , Ginkgo biloba , Plant Extracts , Plant Leaves , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Animals , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Mice , Male , Plant Leaves/chemistry , NF-kappa B/metabolism , Cognition/drug effects , Signal Transduction/drug effects , Maze Learning/drug effects , Mice, Inbred C57BL , Ginkgo Extract
13.
Acta Cir Bras ; 39: e395024, 2024.
Article in English | MEDLINE | ID: mdl-39258617

ABSTRACT

PURPOSE: Hibiscus sabdariffa (HS) extract has several health benefits and anti-obesogenic effects. The aim of the present study was to assess whether the medicinal properties attributable to HS would prevent or mitigate bladder changes induced by obesity in an experimental model. METHODS: Forty-eight male Wistar rats were submitted to one of four different dietary interventions (12 animals each): G1, standard diet and water (controls); G2, standard diet and HS tea; G3, a palatable high-fat diet and water; and G4, high-fat diet diet and HS tea. The animals were monitored for body weight, feed, and water and tea intake, according to the allocated group. After 16 weeks, the animals were euthanized, and the levels of creatinine, inflammatory cytokines, testosterone, cholesterol, triglycerides, and electrolytes were evaluated. In addition, histopathological analysis of the animals' bladder was performed. RESULTS: Groups receiving HS (G2 and G4) showed decreased levels of the pro-inflammatory cytokine interleukin-1α. HS tea was able to reduce low-density lipoprotein and triglyceride levels in the G2 group compared to other groups. Only in the G3 there was a significant increase in the body weight when it was compared the 12th and 16th weeks. Leptin was shown to be elevated in the groups that received a high-fat diet. There was a significant decrease in the muscle fibers thickness and in the total collagen count in G4 bladder when compared with G1 and G3. CONCLUSIONS: HS has an anti-inflammatory role, can reverse hyperlipidemia in rats, and reduced deleterious effects of obesity on these animals' bladder.


Subject(s)
Diet, High-Fat , Hibiscus , Obesity , Plant Extracts , Rats, Wistar , Urinary Bladder , Animals , Hibiscus/chemistry , Male , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Urinary Bladder/drug effects , Urinary Bladder/pathology , Diet, High-Fat/adverse effects , Rats , Dietary Supplements , Body Weight/drug effects , Triglycerides/blood , Disease Models, Animal , Reproducibility of Results , Leptin/blood
14.
Acta Cir Bras ; 39: e397424, 2024.
Article in English | MEDLINE | ID: mdl-39258621

ABSTRACT

PURPOSE: Blackberries are rich in polyphenols and are a human health food continuously consumed to improve health and reduce diseases caused by aging. Herein, we evaluated the effects of daily blackberry administration before and after transient cerebral ischemia in gerbils. METHODS: Blackberry extract (BBE) was orally administered twice a day for two weeks to protect against ischemic events during continuous administration. On the seventh day after administration, the bilateral common carotid arteries were transiently occluded for 5 min. To verify its therapeutic effect, BBE was administered after ischemia using a similar protocol without pre-administration. In both experiments, the number of viable neurons in the CA1 region of the hippocampus was assessed seven days after ischemic treatment. RESULTS: The number of neurons in the group treated with BBE before ischemia was higher than that in the group treated with distilled water (p = 0.0601), and similar to that in the control group. In the BBE administration experiments after ischemia, the number of neurons was significantly reduced compared to that in the control group (p < 0.0001). CONCLUSIONS: Continuous BBE intake is expected to prevent or ameliorate ischemic events such as transient cerebral ischemia.


Subject(s)
Disease Models, Animal , Gerbillinae , Ischemic Attack, Transient , Plant Extracts , Animals , Plant Extracts/therapeutic use , Plant Extracts/pharmacology , Ischemic Attack, Transient/drug therapy , Male , Neurons/drug effects , Time Factors , Neuroprotective Agents/therapeutic use , Reproducibility of Results , Treatment Outcome , Cell Count
15.
Medicine (Baltimore) ; 103(22): e38480, 2024 May 31.
Article in English | MEDLINE | ID: mdl-39259058

ABSTRACT

INTRODUCTION: Toxicity and resistance to chemotherapy used to treat leishmaniasis are increasing. Research on natural plant compounds has revealed their antileishmanial effects on certain Leishmania organisms. This review aimed to estimate the pooled IC50 values of medicinal plants with promising antileishmanial activity in Ethiopia. METHODS: A systematic literature search was conducted using Science Direct, PubMed, Cochrane Library, and Google Scholar to locate potential studies. Studies published in peer-reviewed journals and gray literature in university repositories before April 1, 2022, which included a full-length study reporting the half-maximal inhibitory concentration (IC50) of Ethiopian medicinal plants that were written in English were included. Conference proceedings, review articles, letters to the editor, and correspondence were excluded. The quality of the included studies was assessed using the GIVIMP critical appraisal tools. Heterogeneity between studies was verified using Cochrane Q test statistics and I2 test statistics, and the effects were checked using Egger statistical test at a level of significance. A random-effects model was used to estimate the pooled IC50 of the medicinal plants. RESULTS: Six articles that were conducted in Ethiopia that fulfilled the inclusion criteria, with a total of 62 in vitro experiments, were reviewed. The aggregated mean IC50 for medicinal plants in Ethiopia was 16.80 (95% CI: 12.44, 21.16) and 13.81 (95% CI: 13.12, 14.50) µg/mL for antipromastigote and antiamastigote activity, respectively. Aqueous was the significant preparation with IC50 of 0.53 (0.34, 0.73) µg/mL against promastigote and 0.98 (0.20, 1.76) µg/mL against the amastigote stage. DISCUSSION: This review indicated that the pooled mean of IC50 for Ethiopian medicinal plants against promastigotes and amastigotes was relatively low and showed better efficacy. This strongly suggests the need to focus on antipromastigote and antiamastigote medicinal plants in Ethiopia for the development of antileishmanial drugs. It is necessary to identify their active components, and their potential toxic effects can lead to the production of well-tolerated and safe drugs for leishmaniasis. The high heterogeneity is the limitation of this study. REGISTRATION: The review has been registered at Prospero with identification number CRD42022343543.


Subject(s)
Antiprotozoal Agents , Plants, Medicinal , Ethiopia , Plants, Medicinal/chemistry , Antiprotozoal Agents/pharmacology , Antiprotozoal Agents/therapeutic use , Humans , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Inhibitory Concentration 50 , Leishmaniasis/drug therapy , Leishmania/drug effects
16.
Medicine (Baltimore) ; 103(22): e38289, 2024 May 31.
Article in English | MEDLINE | ID: mdl-39259072

ABSTRACT

BACKGROUND: Ginger, a potent antiviral, anti-inflammatory, and antioxidant remedy, is a potential therapeutic option for COVID-19. However, there was not enough clinical evidence about ginger and COVID-19. We evaluated the efficacy and safety of ginger on clinical and paraclinical features in outpatients with COVID-19. METHODS: In this randomized controlled trial, the outpatients with confirmed COVID-19 were randomly assigned in a 1:1 ratio to receive ginger (1000 mg 3 times a day for 7 days) or placebo. The primary outcome was viral clearance after the end of the intervention. Oxygen saturation (SPO2), body temperature, respiratory rate (RR), hospital admission, and the incidence of adverse events were also assessed. RESULTS: A total of 84 patients (42 in the ginger and 42 in the control groups) were randomized. The viral clearance was not statistically improved in the ginger group (41.6%) compared to the placebo group (42.8%). The findings indicated that SPO2, body temperature, and RR had no significant difference between the groups at the end of the intervention. The imaging finding indicated pulmonary infiltrate significantly reduced on the 7th day of the intervention in the ginger group. The percentage of patients with SPO2 <96% in the ginger group decreased over the study compared to the placebo group. Moreover, the need for hospital admission and the incidence of adverse drug events were not different between the groups over the follow-up period. CONCLUSIONS: Ginger had no significant impact on the clinical and paraclinical parameters of patients. However, this intervention demonstrated a safe profile of adverse events and reduced pulmonary infiltrate. TRIAL REGISTRATION: The trial was registered as IRCT20200506047323N1.


Subject(s)
COVID-19 Drug Treatment , COVID-19 , Plant Extracts , SARS-CoV-2 , Zingiber officinale , Humans , Male , Female , Double-Blind Method , Middle Aged , Plant Extracts/therapeutic use , Plant Extracts/adverse effects , Adult , Rhizome , Outpatients , Treatment Outcome , Antiviral Agents/therapeutic use , Aged , Body Temperature/drug effects
17.
Medicine (Baltimore) ; 103(22): e38319, 2024 May 31.
Article in English | MEDLINE | ID: mdl-39259086

ABSTRACT

The Ankaferd Blood Stopper (ABS) proves effective in managing various bleedings, particularly in surgical and dental procedures. This study assesses ABS efficacy endoscopically by less-experienced endoscopists for non-variceal upper gastrointestinal bleeding (NVUGB). Between 2016 and 2021, our hospital's Gastroenterology Department Endoscopy Unit conducted a retrospective data analysis of 653 patients who underwent endoscopy for NVUGB. The study included 202 patients who underwent endoscopic interventions performed by endoscopists with less than 3 years of experience. Based on the method used for endoscopic hemostasis, we classified those treated with ABS (either alone or as a second method) as group 1. In contrast, we classified patients treated with non-ABS hemostatic methods into Group 2. The study included 202 patients, with 96 (47.52%) in Group 1 and 106 (52.48%) in Group 2. All patients in Group 1 achieved bleeding control, while 4 patients in Group 2 initially did not achieve bleeding control; however, bleeding control was subsequently established following ABS administration. After 1 month of follow-up, mortality occurred in 3 out of 202 patients (1.48%), and all these cases were in Group 2. There is a significant difference in the need for blood transfusion between the groups (P < .001). Regarding the bleeding source, bulbus ulcer and gastric cancer were more prevalent in Group 2. On the other hand, although statistical significance was not reached in the comparison of rebleeding rates between groups, numerically, a higher incidence of recurrent bleeding was observed in Group 2 (Group 1: 3 [3.1%], Group 2: 8 [7.5%]; P = .167). Additionally, a similar relationship was noted among intensive care admissions (Group 1: 5 [5.2%]; Group 2: 7 [6.6%]; P = .675). In the group that used ABS, there were significantly higher rates of hypotension, tachycardia, syncope, and the need for transfusion than in the other group. In medical practice, this distinction often stems from the shared preference of clinicians to use ABS as a salvage method in cases of more severe bleeding. Considering all the findings, it is evident that using ABS through endoscopy in cases of NVUGIB significantly improves procedural success, irrespective of the endoscopist's experience level.


Subject(s)
Gastrointestinal Hemorrhage , Plant Extracts , Humans , Male , Gastrointestinal Hemorrhage/drug therapy , Female , Retrospective Studies , Middle Aged , Aged , Plant Extracts/therapeutic use , Hemostasis, Endoscopic/methods , Hemostatics/therapeutic use , Gastroenterologists , Clinical Competence , Adult , Treatment Outcome
18.
J Clin Pediatr Dent ; 48(5): 51-59, 2024 Sep.
Article in English | MEDLINE | ID: mdl-39275820

ABSTRACT

The aim of this systematic review is to comparatively evaluate the Triphala and chlorhexidine mouthwashes efficacies in decreasing plaque formation and gingivitis in children. With a priori-set inclusion and exclusion criteria's and relevant MeSH terms, the PubMed, Cochrane and Ovid SP were scrutinized from the year 1980 to April 2023 for prospective articles. Outcomes evaluated were plaque formation and gingivitis through Plaque index and Gingival index. Five studies were finally included and were analyzed qualitatively and quantitatively. Meta-analysis, was performed using a random effects model. Plaque index (PI) and Gingival Index (GI). There was no significant difference between reduction in the gingivitis and plaque accumulation between Triphala and chlorhexidine mouthwash groups in children (p value 0.83, 0.96).


Subject(s)
Chlorhexidine , Dental Plaque , Gingivitis , Mouthwashes , Humans , Chlorhexidine/therapeutic use , Mouthwashes/therapeutic use , Child , Gingivitis/prevention & control , Gingivitis/drug therapy , Dental Plaque/prevention & control , Plant Extracts/therapeutic use , Anti-Infective Agents, Local/therapeutic use , Dental Plaque Index , Periodontal Index
19.
Int J Mol Sci ; 25(17)2024 Sep 04.
Article in English | MEDLINE | ID: mdl-39273553

ABSTRACT

Osteoarthritis (OA) is an age-related disease characterized by inflammation, pain, articular cartilage damage, synovitis, and irreversible disability. Gynostemma pentaphyllum (Thunb.) Makino (GP), a herbal medicine traditionally used in East Asia for its anti-inflammatory properties, was investigated for its potential to modulate OA pathology and symptoms. This study evaluated GP's efficacy in inhibiting pain, functional decline, and cartilage destruction in monosodium iodoacetate-induced OA and acetic acid-induced writhing models. Additionally, the effects of GP on OA-related inflammatory targets were assessed via mRNA and protein expression in rat knee cartilage and lipopolysaccharide-induced RAW 264.7 cells. The GP group demonstrated significant pain relief, functional improvement, and cartilage protection. Notably, GP inhibited key inflammatory mediators, including interleukin (IL)-1ß, IL-6, matrix metalloproteinases (MMP)-3 and MMP-13, cyclooxygenase-2, and prostaglandin E receptor 2, surpassing the effects of active controls. These findings suggest that GP is a promising candidate for disease-modifying OA drugs and warrants further comprehensive studies.


Subject(s)
Analgesics , Anti-Inflammatory Agents , Gynostemma , Osteoarthritis , Plant Extracts , Animals , Gynostemma/chemistry , Mice , Osteoarthritis/drug therapy , Osteoarthritis/pathology , Osteoarthritis/chemically induced , Osteoarthritis/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , RAW 264.7 Cells , Rats , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Analgesics/pharmacology , Analgesics/therapeutic use , Male , Cartilage, Articular/drug effects , Cartilage, Articular/pathology , Cartilage, Articular/metabolism , Disease Models, Animal , Rats, Sprague-Dawley , Pain/drug therapy
20.
Int J Mol Sci ; 25(17)2024 Sep 09.
Article in English | MEDLINE | ID: mdl-39273680

ABSTRACT

Oral health is essential for both overall health and quality of life. The mouth is a window into the body's health, and nutrition can strongly impact the state of general and oral health. A healthy diet involves the synergistic effect of various nutraceutical agents, potentially capable of conferring protective actions against some inflammatory and chronic-degenerative disorders. Nutraceuticals, mostly present in plant-derived products, present multiple potential clinical, preventive, and therapeutic benefits. Accordingly, preclinical and epidemiological studies suggested a protective role for these compounds, but their real preventive and therapeutic effects in humans still await confirmation. Available evidence suggests that plant extracts are more effective than individual constituents because they contain different phytochemicals with multiple pharmacological targets and additive/synergistic effects, maximizing the benefits for oral health. Moreover, nutritional recommendations for oral health should be personalized and aligned with valid suggestions for overall health. This review is aimed to: introduce the basic concepts of nutraceuticals, including their main food sources; examine the logic that supports their relationship with oral health, and summarize and critically discuss clinical trials testing the utility of nutraceuticals in the prevention and treatment of oral diseases.


Subject(s)
Dietary Supplements , Oral Health , Humans , Plant Extracts/therapeutic use , Plant Extracts/pharmacology , Phytochemicals/therapeutic use , Phytochemicals/pharmacology , Quality of Life , Animals
SELECTION OF CITATIONS
SEARCH DETAIL